100 related articles for article (PubMed ID: 10078108)
21. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma.
Schlosshauer PW; Pirog EC; Levine RL; Ellenson LH
Mod Pathol; 2000 Oct; 13(10):1066-71. PubMed ID: 11048799
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
23. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
24. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
25. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
26. Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.
Culton LK; Deavers MT; Silva EG; Liu J; Malpica A
Am J Surg Pathol; 2006 Jul; 30(7):844-9. PubMed ID: 16819326
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma.
Lijun Z; Xin Z; Danhua S; Xiaoping L; Jianliu W; Huilan W; Lihui W
Int J Gynecol Cancer; 2012 Jun; 22(5):836-41. PubMed ID: 22617481
[TBL] [Abstract][Full Text] [Related]
28. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract][Full Text] [Related]
29. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role.
Espinosa I; José Carnicer M; Catasus L; Canet B; D'angelo E; Zannoni GF; Prat J
Am J Surg Pathol; 2010 Nov; 34(11):1708-14. PubMed ID: 20962622
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
31. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
32. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas.
Saffari B; Bernstein L; Hong DC; Sullivan-Halley J; Runnebaum IB; Grill HJ; Jones LA; El-Naggar A; Press MF
Int J Gynecol Cancer; 2005; 15(5):952-63. PubMed ID: 16174251
[TBL] [Abstract][Full Text] [Related]
33. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus.
Moore RG; Miller CM; Brown AK; Robison K; Steinhoff M; Lambert-Messerlian G
Int J Gynecol Cancer; 2011 Oct; 21(7):1185-90. PubMed ID: 21720250
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
35. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects.
Clement PB; Young RH
Adv Anat Pathol; 2002 May; 9(3):145-84. PubMed ID: 11981113
[TBL] [Abstract][Full Text] [Related]
36. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
37. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.
Spoelstra NS; Manning NG; Higashi Y; Darling D; Singh M; Shroyer KR; Broaddus RR; Horwitz KB; Richer JK
Cancer Res; 2006 Apr; 66(7):3893-902. PubMed ID: 16585218
[TBL] [Abstract][Full Text] [Related]
38. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma.
Planagumà J; Abal M; Gil-Moreno A; Díaz-Fuertes M; Monge M; García A; Baró T; Xercavins J; Reventós J; Alameda F
J Pathol; 2005 Dec; 207(4):422-9. PubMed ID: 16175655
[TBL] [Abstract][Full Text] [Related]
40. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors.
Sturgeon SR; Sherman ME; Kurman RJ; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD; Brinton LA
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):231-5. PubMed ID: 9521439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
